Proposed changes [Two-Stage / GS Designs]

posted by Mauricio Sampaio  – Brazil, 2020-02-17 13:50 (654 d 12:15 ago) – Posting: # 21177
Views: 4,186

» Consequences for the Consulta Pública N° 760.

Instead of: "Type I error must be preserved and adjusted, and to demonstrate bioequivalence the level of confidence is 94.12%;"

I will only propose that: It must be demonstrated that the type I error of the study is controlled.

Instead of: "This second group must have at least 50% of the previous group"

I will propose that: The number of participants in the second stage must be calculated based on the data extracted from the first stage. The calculation must be justified considering possible losses and / or dropouts observed in the first stage.

In this way, the dialogue is open and not restricted. = "on top of the wall"

[image]


Edit: Subject line changed; see also this post #2. [Helmut]

Complete thread:

Activity
 Admin contact
21,785 posts in 4,556 threads, 1,547 registered users;
online 10 (1 registered, 9 guests [including 6 identified bots]).
Forum time: Friday 02:05 CET (Europe/Vienna)

A drug is that substance which, when injected into a rat,
will produce a scientific report.    Anonymous

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5